Google's Agent Development Kit for Java reached 1.0, introducing integrations with new external tools, a new app and plugin architecture, advanced context engineering, human-in-the-loop workflows, and ...

ARK Invest bought 1.25M shares of Recursion Pharmaceuticals for $4.33M ARK added 37,075 CRISPR Therapeutics shares worth $1.97M PagerDuty was the biggest sell at $3.89M for 566,650 shares ARK also cut ...

Physical activity (PA) is widely recognized as an important factor in promoting children’s cognitive function (CF), yet existing research lacks systematic integration into physical education (PE) ...

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

aRobert N. Butler Columbia Aging Center, Columbia University, New York, NY, USA bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA cCarolina ...